todays trade, page-112

Fair points, but i'd be surprised if a company as big as POC1 that is playing as hardball as it is would be able to stomach 5%?

Perhaps that's why they're playing hard ball, Geoff has certainly been around the traps, his time at Roche should give him the gravitas in negotiations to put out some pretty ballsy offers I'd imagine...

Agree with you Smilez that if this new device is as good as lab analysers and stable enough to be deployed to GP's, ED's and Ambulances it should rack up massive sales quickly. You'd want to see some quality studies proving its real world application and performance too, but these should only take a few months (ideally prior to launch). You'd also want the device to be able to perform other tests, although Troponin is the obvious stand out that would get the product noticed quickly.

I still feel BBI has much more to offer near term.